Home Title

Transforming lives by delivering convenience through specialist expertise.

Transforming lives by delivering convenience through specialist expertise.

Transforming lives by delivering convenience through specialist expertise.

COVID 19

Following updated Government and Health Authority advice, to reduce the spread of COVID 19 and to reduce any risks to our employees, all employees across the Group are working from home, aside from those critical to the continued manufacture of our products. As part of our commitment to putting patients first, we are continually monitoring our supply chain and manufacturing capabilities and are confident that we will continue to be able to supply our allergy therapies and diagnostics. We continue to monitor the situation and are committed to maintain our mission of transforming allergy treatment.

+8% Revenue growth (both reported and constant currency rate)
22% Increase in pre-R&D operating profit to £11.3m (2018: £9.3m)
£27.4m Strong cash balance at 30 June 2019 (2018: £15.5m)
£3.5m Net profit for the year including Inflamax settlement of £6m (2018: Net loss of £7.5m)

Our year in numbers

2019 was a year of continued growth with constant currency growth of 8%, a 0.5 point increase in our market share to 14.1% and an increase in operating profit before R&D of 22%.

Annual Report 2019

Take your career to new heights

Our culture and values